SUPN · Healthcare
SUPERNUS PHARMACEUTICALS
Smart-money confidence
· 1 of 3 sources firing
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in SUPERNUS PHARMACEUTICALS? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$2.7B
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Exchange
NasdaqGM
About SUPERNUS PHARMACEUTICALS
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent…
Who's behind the signal
Every informed buyer we can see on SUPN, across all three feeds.
Hedge funds · 6
Point72 (Steve Cohen)
Increased +29%
Millennium Management (Englander)
Increased +662%
Tudor Investment (Paul Tudor Jones)
Increased +11%
D.E. Shaw & Co
Decreased −28%
Citadel Advisors
Decreased −68%
AQR Capital Management
Decreased −8%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trade history · 4
Every disclosed buy & sell on record — STOCK Act filings
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2020-11-13 | Gilbert Ray Cisneros, Jr. · D-CA | House | BOUGHT | $1,001 - $15,000 |
| 2020-07-17 | Gilbert Ray Cisneros, Jr. · D-CA | House | BOUGHT | $1,001 - $15,000 |
| 2020-06-01 | Gilbert Ray Cisneros, Jr. · D-CA | House | BOUGHT | $1,001 - $15,000 |
| 2020-05-28 | Josh Gottheimer · D-NJ | House | BOUGHT | $1,001 - $15,000 |
Not a model pick — but on our radar.
SUPERNUS PHARMACEUTICALS isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
3
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.2%
Position change
+29%
0.2% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+662%
0.1% of Millennium Management's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
+11%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−28%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−68%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−8%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to SUPERNUS PHARMACEUTICALS
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell SUPERNUS PHARMACEUTICALS or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime